Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer - A review of the literature

Oncologist

Volumn 12, Issue 2, 2007, Pages 201-210

  Araújo, António ^a,b   Ribeiro, Ricardo ^a,b   Azevedo, Isabel ^a   Coelho, Ana ^a   Soares, Marta ^a   Sousa, Berta ^a   Pinto, Daniela ^a   Lopes, Carlos ^a,b   Medeiros, Rui ^a,b   Scagliotti, Giorgio V ^c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Epidermal growth factor; Epidermal growth factor receptor; Non small cell lung cancer; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

GENETIC POLYMORPHISM; HUMAN; LITERATURE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847056277     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-2-201     Document Type: Review

References (89)

1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol 2005;23:3175-3185.
2. Herbst RS, Bajorin DF, Bleiberg H et al. Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2006;24:190-205.
3. Pisani P, Parkin DM, Bray F et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:870-873.
4. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tobacco Control 1994;3:242-247.
5. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
6. Naruke T, Tsuchiya R, Kondo H et al. Implications of staging in lung cancer. Chest 1997;112:242s-248s.
7. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
8. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-747.
9. Aaronson SA. Growth factors and cancer. Science 1991;254:1146-1153.
10. Goustin AS, Leof AB, Shipley GD. Growth factors and cancer. Cancer Res 1986;46:1015-1029.
11. Tabernero J, Macarulla T, Ramos FJ et al. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-1748.
12. Fan Z, Lu Y, Wu X et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269:27595-27602.
13. Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
14. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
15. Yan L, Beckman RA. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 2005;39:565-568.
16. Sachidanandam R, Weissman D, Schmidt SC et al. International SNP Map Working Group: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.
17. Medeiros RM, Morais A, Vasconcelos A et al. Outcome in prostate cancer: Association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7. Clin Cancer Res 2002;8:3433-3437.
18. Medeiros R, Pereira D, Afonso N et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: Glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003;8:156-161.
19. Medeiros R, Vasconcelos A, Costa S et al. Metabolic susceptibility genes and prostate cancer risk in a southern European population: The role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms. Prostate 2004;58:414-420.
20. Coelho A, Calçada C, Catarino R et al. CXCL12-3′ A polymorphism and lung cancer metastases protection: New perspectives in immunotherapy? Cancer Immunol Immunother 2005;6:1-5.
21. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004;429:464-468.
22. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-176.
23. Ribeiro R, Araújo AP, Coelho A et al. A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer. Eur J Cancer 2006;42:1188-1193.
24. Shepherd FA, Tsao MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 2006;24:1219-1223.
25. Davies RL, Grosse VA, Kucherlapati R et al. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor to chromosome 7. Proc Natl Acad Sci U S A 1980;77:4188-4192.
26. Haley J, Whittle N, Bennet P et al. The human EGF receptor gene: Structure of the 110 kb locus and identification of sequences regulating its transcription. Oncogene Res 1987;1:375-396.
27. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
28. Olayioye MA, Neve RM, Lane HA et al. The ErbB signalling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167.
29. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
30. Scagliotti GV, Selvaggi G, Novello S et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227s-4232s.
31. Laskin JJ, Sandler AB. Epidermal growth factor receptor: A promising target in solid tumours. Cancer Treat Rev 2004;30:1-17.
32. Akimoto T, Hunter NR, Buchmiller L et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5:2884-2890.
33. Barker FG 2nd, Simmons ML, Chang SM et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-418.
34. Sheridan MT, O'Dwyer T, Seymour CB et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig 1997;5:180-186.
35. Carraway KL 3rd, Weber JL, Unger MJ et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997;387:512-516.
36. Chang H, Riese II DJ, Gilbert W et al. Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 1997;387:509-512.
37. Harari D, Tzahar E, Romano J et al. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999;18:2681-2689.
38. Zhang D, Sliwkowski MX, Mark M et al. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A 1997;94:9562-9567.
39. Riese DJ II, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41-48.
40. Karunagaran D, Tzahar E, Beerli RR et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer. EMBO J 1996;15:254-264.
41. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-8874.
42. Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. The Oncologist 2003;8(suppl 3):5-17.
43. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000;103:211-225.
44. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
45. Perez-Soler R, Chachoua A, Hammond L et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
46. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
47. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
48. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increase copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-6837.
49. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
50. Johnson BE, Jänne PA. Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? J Clin Oncol 2005;23:6813-6816.
51. Chi DD, Hing AV, Helms C et al. Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro α 2 (I) collagen (COL1A2). Hum Mol Genet 1992;1:135.
52. Roetger A, Brandt B, Barnekow A. Competitive-differential polymerase chain reaction for gene dosage estimation of erbB-1 (egfr), erbB-2, and erbB-3 oncogenes. DNA Cell Biol 1997;16:443-448.
53. Gebhardt F, Bürger H, Brandt B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations - a link between genetics and epigenetics. Histol Histopathol 2000;15:929-936.
54. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999;274:13176-13180.
55. Buerger H, Gebhardt F, Schmidt H et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of EGFR is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-857.
56. Liu W, Innocenti F, Chen P et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012.
57. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
58. Amador ML, Oppenheimer D, Perea S et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-9143.
59. Dubey S, Stephenson P, Levy DE et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006;1:406-412.
60. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000;343:1217-1222.
61. Hirsch FR. EGFR. A prognostic and/or predictive marker? J Thorac Oncol 2006;1:395-397.
62. Ishii S, Xu YH, Stratton RH et al. Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A 1985;82:4920-4924.
63. Johnson AC, Ishii S, JinnoY et al. Epidermal growth factor receptor gene promoter: Deletion analysis and identification of nuclear protein binding sites. J Biol Chem 1988;263:5693-5699.
64. Fromm M, Berg P. Deletion mapping of DNA regions required for SV40 early region promoter function in vivo. J Mol Appl Genet 1982;1:457-481.
65. Dynan WS, Sazer S, Tijian R et al. Transcription factor Sp1 recognizes a DNA sequence in the mouse dihydrofolate reductase promoter. Nature 1986;319:246-248.
66. Vallian S, Chin KV, Chang KS. The promyelocytic leukaemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol Cell Biol 1998;18:7147-7156.
67. Kageyama R, Merlino GT, Pastan I. Epidermal growth factor (EGF) receptor gene transcription: Requirement for Sp1 and an EGF receptor-specific factor. J Biol Chem 1988;263:6329-6336.
68. Xu J, Thompson KL, Shephard LB et al. T3 receptor suppression of Sp1-dependent transcription from the epidermal growth factor receptor promoter via overlapping DNA-binding sites. J Biol Chem 1993;268:16065-16073.
69. Grinstein E, Jundt F, Weinert I et al. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene 2002;21:1485-1492.
70. Liu W, Innocenti F, Wu MH et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53.
71. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
72. Lee JW, Soung YH, Kim SY et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 2005;113:510-511.
73. Arteaga CL. Selecting the right patient for tumor therapy. Nat Med 2004;10:577-578.
74. Laurence DJ, Gusterson BA. The epidermal growth factor: A review of structural and functional relationships in the normal organism and in cancer cells. Tumor Biol 1990;11:229-261.
75. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-7712.
76. Salomon DS, Brandt R, Ciardello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
77. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-8895.
78. Normanno N, Bianco C, De Luca A et al. Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 2003;10:1-21.
79. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signalling in cancer. Gene 2006;366:2-16.
80. Shahbazi M, Pravica V, Nasreen N et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
81. Mackie RM, Aitchison T, Sirel JM et al. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. Br J Cancer 1995;71:173-176.
82. McCarron SL, Bateman AC, Theaker JM et al. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 2003;107:673-675.
83. Amend KL, Elder JT, Tomsho LP et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 2004;64:2668-2672.
84. James MR, Hayward NK, Dumenil T et al. EGF polymorphism and risk of melanocytic neoplasia. J Invest Dermatol 2004;123:760-762.
85. Randerson-Moor SL, Gaut R, Turner F. The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G, and melanoma/nevus susceptibility. J Invest Dermatol 2004;123:755-759.
86. Howell WM. Epidermal growth factor gene polymorphism and development of cutaneous melanoma. J Invest Dermatol 2004;123:xx-xxi.
87. Bhowmick DA, Zhuang Z, Wait SD et al. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64:1220-1223.
88. Hamai Y, Matsumura S, Matsusaki K et al. A single nucleotide polymorphism in the 5′ untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 2005;72:133-138.
89. Goto Y, Ando T, Goto H et al. No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2454-2456.